Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 133

Sort by

Sort Order Select

Journal Articles

Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma

James K. Godfrey, Lei Gao, Geoffrey Shouse, Joo Y. Song, Stacy Pak, Brian Lee, Bihong T. Chen, Avyakta Kallam, John H. Baird, Guido Marcucci, Lucy Ghoda, Stephanie Vauleon, Alexey V. Danilov, Alex F. Herrera, Larry W. Kwak, Lihua E. Budde

Blood (2024) 144 (4): 457–461.

https://doi.org/10.1182/blood.2024024168

Published: 2024

Includes: Supplemental data

Journal Articles

Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Nathalie A. Johnson, David Lavie, Peter Borchmann, Gareth P. Gregory, Alex F. Herrera, Leonard Minuk, Vladan Vucinic, Philippe Armand, Abraham Avigdor, Robin Gasiorowski, Yair Herishanu, Colm Keane, John Kuruvilla, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, John Timmerman

Blood (2023) 142 (Supplement 1): 1693.

https://doi.org/10.1182/blood-2023-182128

Published: 2023

Journal Articles

Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008

David Lavie, John Timmerman, Ramón García-Sanz, Won Seog Kim, Tae Min Kim, Abraham Avigdor, Daan Dierickx, Deepa Jagadeesh, Daniel L. Molin, Muhit Ozcan, Omur Gokmen Sevindik, Hayder Saeed, Yulia Sidi, Pallavi Pillai, Patricia Marinello, Alex F. Herrera

Blood (2023) 142 (Supplement 1): 3082.

https://doi.org/10.1182/blood-2023-182119

Published: 2023

Journal Articles

PD-1 Blockade before Autologous Stem Cell Transplantation Improves Outcomes in Relapsed/Refractory Classic Hodgkin Lymphoma: Results from a Multicenter Cohort

Blood (2023) 142 (Supplement 1): 182.

https://doi.org/10.1182/blood-2023-179573

Published: 2023

Journal Articles

Plasma Circulating Tumor DNA (ctDNA) as an Alternative to Tissue DNA for Genotyping of DLBCL: Results from the POLARIX Study

Fabrice Jardin, Vibha Raghavan, Samuel Tracy, Sandhya Balasubramanian, Laurie H. Sehn, Christopher R. Flowers, Franck Morschhauser, Alex F. Herrera, Marek Trněný, Jeff P. Sharman, Gilles Salles, Hervé Tilly, Jonathan W. Friedberg, Will Harris, Jamie H. Hirata, Calvin Lee, Yanwen Jiang, Georg Lenz

Blood (2023) 142 (Supplement 1): 169.

https://doi.org/10.1182/blood-2023-178564

Published: 2023

Journal Articles

Longitudinal Analysis of Circulating Tumor DNA (ctDNA) in Diffuse Large B-Cell Lymphoma (DLBCL) Using KAPA HyperCap Design Share Non-Hodgkin Lymphoma (KAPA HyperCap DS NHL) Next-Generation Sequencing (NGS) Panel

Vladislava Melnikova, Clara Bermejo, Richard Chien, Parul Agarwal, Alexandra Markus, Bowdoin Su, Renee Stokowski, Ronald McCord, Alex F. Herrera, Laurie H. Sehn

Blood (2023) 142 (Supplement 1): 6082.

https://doi.org/10.1182/blood-2023-182093

Published: 2023

Journal Articles

The Combination of Nivolumab and CC-486 Is Active in Hodgkin Lymphoma Refractory to PD-1 Blockade

Matthew G. Mei, Lu Chen, Sandrine Puverel, L. Elizabeth Budde, Swetha Kambhampati, Shari Daniels, Bev Dunning, Melissa Banez, Larry W. Kwak, Alex F. Herrera

Blood (2023) 142 (Supplement 1): 1697.

https://doi.org/10.1182/blood-2023-190753

Published: 2023

Journal Articles

A Personalized Whole Genome-Informed Assay Targeting Single Mutant in Circulating Tumor DNA Can Identify MRD and Predict Relapse in DLBCL

Blood (2023) 142 (Supplement 1): 527.

https://doi.org/10.1182/blood-2023-189962

Published: 2023

Journal Articles

Autologous Transplant (auto-HCT) Is Associated with Improved Clinical Outcomes Compared to CAR-T Therapy in Patients (pts) with Large B-Cell Lymphoma (LBCL) Achieving a Complete Remission

Mazyar Shadman, Kwang Wooahn, Manmeet Kaur, Mohamed A. Kharfan-Dabaja, Alex F. Herrera, Craig S Sauter, Mehdi Hamadani

Blood (2023) 142 (Supplement 1): 781.

https://doi.org/10.1182/blood-2023-173536

Published: 2023

Journal Articles

Efficacy of Brentuximab Vedotin Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma with and without Pre-Transplant Exposure to Novel Agents

Blood (2023) 142 (Supplement 1): 3062.

https://doi.org/10.1182/blood-2023-182318

Published: 2023

Journal Articles

Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study

Blood (2023) 142 (Supplement 1): 3000.

https://doi.org/10.1182/blood-2023-178623

Published: 2023

Journal Articles

Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Hodgkin Lymphoma across the United States

Blood (2023) 142 (Supplement 1): 3071.

https://doi.org/10.1182/blood-2023-174589

Published: 2023

Journal Articles

Engraftment Syndrome during Autologous Stem Cell Transplant in Hodgkin Lymphoma Patients Treated with Checkpoint Inhibitors: A Multi-Center Retrospective Analysis

Eleanor Taranto, Wei-Ting Hwang, Maria Alfaro, Annika S Surapaneni, Sarvarinder Kaur Gill, Tatyana Feldman, Michael P Randall, Michael A Spinner, Fateeha Furqan, Nirav N. Shah, Yazeed Samara, Matthew G. Mei, Alex F. Herrera, Alison Moskowitz, Gunjan L. Shah, Jakub Svoboda

Blood (2023) 142 (Supplement 1): 3603.

https://doi.org/10.1182/blood-2023-187199

Published: 2023

Journal Articles

Chimeric Antigen Receptor (CAR) T Cell Infusion for Large B Cell Lymphoma in Complete Remission: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Trent Wang, Kwang Wooahn, Manmeet Kaur, Mazyar Shadman, Alex F. Herrera, Craig S Sauter, Mehdi Hamadani, Antonio M. Jimenez Jimenez

Blood (2023) 142 (Supplement 1): 615.

https://doi.org/10.1182/blood-2023-179223

Published: 2023

Journal Articles

Impact of Peri-Transplant Radiation on Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant

Blood (2023) 142 (Supplement 1): 4436.

https://doi.org/10.1182/blood-2023-173470

Published: 2023

Journal Articles

3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Julio C. Chavez, Michael Dickinson, Javier L. Munoz, Matthew L. Ulrickson, Catherine Thieblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S Ujjani, Yi Lin, Peter A. Riedell, Natasha K. Kekre, Sven de Vos, Christine Lui, Jacob Wulff, Chad M. Williams, Weixin Peng, Ioana Kloos, Hairong Xu, Sattva S. Neelapu

Blood (2023) 142 (Supplement 1): 894.

https://doi.org/10.1182/blood-2023-174510

Published: 2023

Journal Articles

Comparative Effectiveness of Axicabtagene Ciloleucel Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

Blood (2023) 142 (Supplement 1): 2121.

https://doi.org/10.1182/blood-2023-178629

Published: 2023

Journal Articles

Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

John Timmerman, David Lavie, Nathalie A. Johnson, Abraham Avigdor, Peter Borchmann, Charalambos Andreadis, Ali Bazargan, Gareth P. Gregory, Colm Keane, Inna Tzoran, Vladan Vucinic, Pier Luigi Zinzani, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, Alex F. Herrera

Blood (2023) 142 (Supplement 1): 4440.

https://doi.org/10.1182/blood-2023-182019

Published: 2023

Journal Articles

Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma

Swetha Kambhampati, Reid W. Merryman, Yan Wang, Evandro Bezerra, Timothy Voorhees, Ayo S Falade, Madhav R Seshadri, Megumi Bailey, Neil Bailey, Krish Patel, Charalambos Andreadis, Adam S Kittai, Caron A Jacobson, Joycelynne Michelle Palmer, Annette Brown, Alex F. Herrera, L. Elizabeth Budde

Blood (2023) 142 (Supplement 1): 3511.

https://doi.org/10.1182/blood-2023-182467

Published: 2023

Journal Articles

Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

Blood (2023) 142 (Supplement 1): 610.

https://doi.org/10.1182/blood-2023-180107

Published: 2023

NARROW

Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma

Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008

PD-1 Blockade before Autologous Stem Cell Transplantation Improves Outcomes in Relapsed/Refractory Classic Hodgkin Lymphoma: Results from a Multicenter Cohort

Plasma Circulating Tumor DNA (ctDNA) as an Alternative to Tissue DNA for Genotyping of DLBCL: Results from the POLARIX Study

Longitudinal Analysis of Circulating Tumor DNA (ctDNA) in Diffuse Large B-Cell Lymphoma (DLBCL) Using KAPA HyperCap Design Share Non-Hodgkin Lymphoma (KAPA HyperCap DS NHL) Next-Generation Sequencing (NGS) Panel

The Combination of Nivolumab and CC-486 Is Active in Hodgkin Lymphoma Refractory to PD-1 Blockade

A Personalized Whole Genome-Informed Assay Targeting Single Mutant in Circulating Tumor DNA Can Identify MRD and Predict Relapse in DLBCL

Autologous Transplant (auto-HCT) Is Associated with Improved Clinical Outcomes Compared to CAR-T Therapy in Patients (pts) with Large B-Cell Lymphoma (LBCL) Achieving a Complete Remission

Efficacy of Brentuximab Vedotin Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma with and without Pre-Transplant Exposure to Novel Agents

Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study

Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Hodgkin Lymphoma across the United States

Engraftment Syndrome during Autologous Stem Cell Transplant in Hodgkin Lymphoma Patients Treated with Checkpoint Inhibitors: A Multi-Center Retrospective Analysis

Chimeric Antigen Receptor (CAR) T Cell Infusion for Large B Cell Lymphoma in Complete Remission: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Impact of Peri-Transplant Radiation on Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant

3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Comparative Effectiveness of Axicabtagene Ciloleucel Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma

Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only